Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-08-15
2009-11-03
Goddard, Laura B (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S158100, C424S178100, C424S183100
Reexamination Certificate
active
07611704
ABSTRACT:
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
REFERENCES:
patent: 4199574 (1980-04-01), Schaeffer
patent: 4287188 (1981-09-01), Schaeffer
patent: 4665062 (1987-05-01), Eriksson et al.
patent: 4771041 (1988-09-01), Eriksson et al.
patent: 5512596 (1996-04-01), Kim et al.
patent: 6300308 (2001-10-01), Schroit
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6486166 (2002-11-01), Albrecht et al.
patent: 6783760 (2004-08-01), Thorpe et al.
patent: 6806354 (2004-10-01), Schroit
patent: 6818213 (2004-11-01), Thorpe et al.
patent: 7067109 (2006-06-01), Thorpe et al.
patent: 7247303 (2007-07-01), Thorpe et al.
patent: 7422738 (2008-09-01), Thorpe et al.
patent: 7455833 (2008-11-01), Thorpe et al.
patent: 2002/0025319 (2002-02-01), Brams
patent: 2003/0004097 (2003-01-01), Schroit
patent: 2004/0219155 (2004-11-01), Thorpe et al.
patent: 2005/0002941 (2005-01-01), Thorpe et al.
patent: WO 00/02584 (2000-01-01), None
patent: WO 00/02587 (2000-01-01), None
patent: WO 01/03735 (2001-01-01), None
patent: WO 01/68709 (2001-09-01), None
Ran et al (Clinical Cancer Research, 2005, 11:1551-1562, IDS).
Luster et al (J of Biological Chemistry, 2006, IDS).
Gait and Karn (TIBTECH, 1995, 13:430-438).
Sidwell et al (Antiviral Research, 2000, 48:1-16, IDS).
Janeway et al (Immunobiology, 2001, 5th Ed., Garland Publishing, New York).
Rote et al (Clinical Immunology and Immunopathology, 1993, 66:193-200, IDS).
Bevers et al (Clinical Immunology, 2004, 112:150-160).
Luster et al (J Biological Chemistry, 2006, 281:29863-71, IDS).
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”.
Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982).
Colman P. M. (Research in Immunology, 145:33-36, 1994).
Bendig M. M. (Methods: A Companion to Methods in Enzymology, 1995; 8:83-93).
MacCallum et al (J. Mol. Biol., 262, 732-745, 1996).
Casset et al (Biochemical and Biophysical Research Communications, 307:198-205, 2003).
Luster et al (J Biological Chemistry, 2006, 281:29863-71).
Ran et al (Clinical Cancer Research, 2005, 11:1551-1562).
Aronson et al., “Pathological and Virological Features of Arenavirus Disease in Guinea Pigs, Comparison of Two Pichinde Virus Strains,”Am. J. Pathol., 145(1):228-235, Jul. 1994.
Balasubramanian & Schroit, “Aminophospholipid Asymmetry: A Matter of Life and Death,”Annu. Rev. Physiol., 65:701-734, 2003.
Callahan et al., “Phosphatidylserine on HIV Envelope is a Cofactor for Infection of Monocytic Cells,”J. Immunol., 170:4840-4845, 2003.
Candurra et al., “Inhibition of Arenavirus multiplication in vitro by phenotiazines,”Antiviral Res., 31:149-158, 1996.
Claryse et al., “In vitro Assays for Drug Testing: Continuous Cell Lines,”Acta Gastro-Enterologica Belgica, vol. LXIII:213-215, 2000.
Cluett et al., “The envelope of vaccinia virus reveals an unusual phospholipid in Golgi complex membranes,”J. Cell Sci., 109:2121-2131, 1996.
Connolly et al., Pathogenesis of Pichinde Virus Infection in Strain 13 Guinea Pigs: An Immunocytochemical, Virologic, and Clinical Chemistry Study,Am. J. Trop. Med Hyg., 49(1):10-24, 1993.
Crumpacker et al., “Growth Inhibition by Acycloguanosine of Herpesviruses Isolated from Human Infections,”Antimicrobial Agents and Chemotherapy, 15(5):642-645, May 1979.
Elion et al., “Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine,”Proc. Natl. Acad. Sci. USA, 74(12):5716-5720, Dec. 1977.
Estepa et al., “Pepscan Mapping and Fusion-Related Properties of the Major Phosphatidylserine-Binding Domain of the Glycoprotein of Viral Hemorrhagic Septicemia Virus, a Salmonid Rhabdovirus,”Virology, 216:60-70, 1996.
Field and Brown, “Animal Models for Antiviral Chemotherapy,”Antiviral Research, 12:165-80, 1989.
Galabov and Galegov, “Methodical Aspects of the Experimental Chemotherapy of Viral Infections,”Acta. Virol, 22:343-351, 1978.
Hu and Hsiung, “Evaluation of New Antiviral Agents: I. In Vitro Perspectives,”Antirival Research, 11:217-232, 1989.
Huang et al., “Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection,”FEBS Lett., 392:59-62, 1996.
Jahrling et al., “Pathogenesis of a Pichinde Virus Strain Adapted to Produce Lethal Infections in Guinea Pigs,”Infect. Immun., 32(2):872-880, May 1981.
Luan et al., “Formation of Membrane Domains Created during the Budding of Vesicular Stomatitis Virus. A Model for Selective Lipid and Protein Sorting in Biological Membranes,”Biochemistry, 34:9874-9883, 1995.
Öberg and Vrang, “Screening for New Agents,”Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471, 1990.
Schaeffer et al., “9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes groups,”Nature, 272:583-585, Apr. 13, 1978.
Schnürer & Öberg, “Inhibitory Effects of Foscarnet on Herpesvirus Multiplication in Cell Culture,”Archives of Virology, 68:203-209, 1981.
Sidewell & Smee, “In vitro and in vivo assay systems for study of influenza virus inhibitors,”Antiviral Res., 48:1-16, 2000.
Thorpe et al., “Tumor Infarction: immunoconjugates that coagulate the vasculature of solid tumors,”Proceeding of the American Association for Cancer Research, 36:488, Abstract #2910, Mar. 1995.
Wahren & Öberg, “Inhibition of Cytomegalovirus Late Antigens by Phosphonoformate,”Intervirology, 12:335-339, 1979.
Wahren & Öberg, “Reversible Inhibition of Cytomegalovirus Replication by Phosphonoformate,”Intervirology, 14:7-15, 1980.
Contractual European Search Report for counterpart PCT Application, PCT/US03/21925, mailed Mar. 31, 2004.
Luster et al., Plasma Protein Beta-2-glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells,JBC Papers in Press, www.jbc.org/cgi/doi/10.1074/jbc., M605252200:1-20, 2006.
Ran et al., “Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice”,Clin. Cancer Res., 11:1551-1562, 2005.
European Search Report for counterpart European Application No. 03764600.7, dated Dec. 27, 2004.
International Search Report for counterpart PCT Application, PCT/US03/21925, mailed Feb. 24, 2005.
Adler et al., “Monoclonal Antiphosphatidylserine Antibody Inhibits Intercellular Fusion of the Choriocarcinoma Line, JAR”,Biology of Reproduction, 53:905-910, 1995.
Ahola et al., “Semliki Forest Virus mRNA Capping Enzyme Requires Association with Anionic Membrane Phospholipids for Activity”,EMBO J., 18(11):3164-3172, 1999.
Aussel et al., “Monoclonal Antibodies Directed Against the E2 Protein (MIC2 Gene Product) Induce Exposure of Phosphatidylserine at the Thymocyte Cell Surface”,Biochemistry, 32:10096-10101, 1993.
Balachandran et al., “Protection Against Lethal Challenge of BALB/c Mice by Passive Transfer of Monoclonal Antibodies to Five Glycoproteins of Herpes Simplex Virus Type 2”,Infect. Immun., 37(3):1132-1137, 1982.
Banki et al., “Molecular Ordering in HIV-Induced Apoptosis”,J. Biol. Chem., 273(19):11944-11953, 1998.
Beck et al., “Combination of a Monoclonal Anti-Phosphatidylserine Antibody with Gemcitabine Strongly Inhibits the Growth
Ran Sophia
Soares M. Melina
Thorpe Philip E.
Board of Regents , The University of Texas System
Fussey Shelley P. M.
Goddard Laura B
LandOfFree
Compositions and methods for treating viral infections using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating viral infections using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating viral infections using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084309